

Contents

Interpreting the Flexibilities Under the TRIPS Agreement	1
Carlos M. Correa	
Intellectual Property Exhaustion and Parallel Imports of Pharmaceuticals: A Comparative and Critical Review	31
Irene Calboli	
Compulsory Licenses and Government Use: Challenges and Opportunities	73
Yousuf A. Vawda	
Access to CRISPR Genome Editing Technologies: Patents, Human Rights and the Public Interest	105
Duncan Matthews	
Bolar Exception	135
Viviana Munoz Tellez	
Patent Oppositions in India	151
Sandeep Kanak Rathod	
Protection of Clinical Test Data and Public Health: A Proposal to End the Stronghold of Data Exclusivity	183
Ellen 't Hoen	
Courts and Pharmaceutical Patents: From Formalist Positivism to the Emergence of a Global Law	201
Calixto Salomão Filho and Vitor Henrique Pinto Ido	
Robust Patent Examination or Deep Harmonization? Cooperation and Work Sharing Between Patent Offices	241
Nirmalya Syam	

Intellectual Property Rights (IPRs), Competition Law and Excessive Pricing of Medicines	277
Mor Bakhoun	
The Impact of ‘TRIPS-Plus’ Rules on the Use of TRIPS Flexibilities: Dealing with the Implementation Challenges	297
Mohammed El Said	
Patent Linkages and Its Impact on Access to Medicines: Challenges, Opportunities for Developing Countries	329
K. D. Raju	